Lack of Treatment Efficacy and Duration of OnabotulinumtoxinA and AbobotulinumtoxinA Post Sars-COV-2 Infection and COVID Vaccination

This article outlines the data collection process we used to document treatment efficacy and longevity changes in 1,298 patients who received a total of 4,583 treatments with either onabotulinumtoxinA, abobotulinumtoxinA, or both during the Sars-COV-2 (COVID-19) pandemic outbreak in 2020 and the adult COVID-19 vaccination program rollout in 2021. We divided the study patients into two groups based on the year they were treated (2020 = 791; 2021 = 1,037). We did not include any new patients in the study. We found that 2.5% (n = 19) of the patients in the 2020 group experienced a lack of treatment effect and 5.2% (n = 40) experienced a decrease in treatment duration. We found that 2.1% (n = 22) of the patients in the 2021 group experienced a lack of treatment effect and 13.6% (n = 141) experienced a decrease in treatment duration. We also identified a sample population of patients who experienced a decrease in treatment duration incidents when receiving the COVID-19 vaccine after their last treatment. Our data show there is an apparent relationship between patients experiencing a lack of treatment efficacy and/or a decrease in treatment duration and having a Sars-COV-2 infection or receiving a COVID-19 vaccine.